

<b>Corporate Liaison Board (CLB) Remit</b>	
<b>Committee Composition</b>	
<b>Members</b>	<ol style="list-style-type: none"> <li>1. Chair</li> <li>2. ESPE Secretary General (ex-officio)</li> <li>3. ESPE Chair of Strategic and Finance Committee (ex-officio)</li> <li>4. ESPE Chair of the Programme Organising Committee (ex-officio)</li> <li>5. ESPE President (ex-officio)</li> <li>6. ESPE President-Elect (ex-officio)</li> </ol>
<b>Co-opted members</b>	As necessary
<b>Other considerations</b>	<ul style="list-style-type: none"> <li>• Meetings are also attended by supporting industry representatives. Gender balance, young members, spread of clinical disciplines (including diabetes, obesity and metabolism) and spread of geographical areas especially across Europe.</li> <li>• All members should attend the meetings where possible.</li> </ul>
<b>Quorum</b>	3 members
<b>Duration of Service</b>	3 years (with possibility to extend for one year or a second term of three years)
<b>Reporting</b>	The Committee reports to the ESPE Council
<b>Meetings</b>	2 meetings per year. One at the annual meeting and one at the annual sponsor site visit.
<b>Minutes</b>	To all members of the CLB and industry representatives.
<b>Administrative Support</b>	<ul style="list-style-type: none"> <li>• Corporate Relations Manager</li> </ul>
<b>Remit</b>	<ul style="list-style-type: none"> <li>• To serve as a forum for two-way communication and advice between ESPE and industry.</li> <li>• To foster partnerships and collaborations between ESPE and industry for the Society's educational and scientific activities.</li> <li>• To ensure industry supporters have knowledge of all sponsorship opportunities of Society educational and scientific projects.</li> <li>• To ensure industry has continued access to the Society leadership.</li> <li>• To help ensure and maintain optimal industry participation in the activities of ESPE, including, where possible and appropriate, the involvement of new companies, whilst ensuring that such support does not influence the scientific content and integrity of ESPE activities.</li> <li>• To secure relationships with industry and financial support for ESPE education and training activities, in partnership with the ESPE Corporate Relations Manager (Bioscientifica).</li> <li>• To discuss with industry representatives new initiatives to enhance the annual meeting and educational and scientific activities, and to enhance working relationships between paediatric endocrinologists and pharma for the benefit of children and young people with endocrine disorders.</li> <li>• Where appropriate (subject to decision of Chair and Council), to manage industry participation in ESPE events, e.g. the Annual Meeting.</li> <li>• Recruit appropriately qualified paediatric endocrinologists working in industry into the Society.</li> <li>• To encourage industry members to present new research at Society meetings during satellite symposia.</li> </ul>
<b>Additional notes</b>	<ul style="list-style-type: none"> <li>• Committee members should make every effort to attend all meetings.</li> <li>• Any Committee member who does not attend a meeting for a year will be asked to step down, other than in exceptional circumstances.</li> <li>• All Committee members need to be paid up members of the Society.</li> <li>• All papers and minutes must be treated in strictest confidence.</li> </ul>

- |  |
|--|
| <ul style="list-style-type: none"><li>• All Committee members must act in the best interest of the Society.</li><li>• Any passwords and logins provided to Committee members to enable their roles should not be shared with anyone.</li><li>• Any potential conflicts of interest should be declared at the start of the meeting or as they arise, and the member concerned should take no part in the discussion.</li><li>• All members can serve a second consecutive term of office or extend their term for one year.</li></ul> |
|--|